Literature DB >> 29608816

Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system.

Chia-Yang Hsu1,2,3, Po-Hong Liu1,2,4, Shu-Yein Ho1,2, Yi-Hsiang Huang1,5, Yun-Hsuan Lee1,2, Rheun-Chuan Lee2,6, Teddy S Nagaria7, Ming-Chih Hou1,2, Teh-Ia Huo1,2,8.   

Abstract

BACKGROUND & AIM: Patients with hepatocellular carcinoma and metastasis are classified as advanced or terminal stage by the Barcelona Clinic Liver Cancer system. This study investigates the prevalence, determinants, and prognostic effect of metastasis and its ability to improve the Barcelona Clinic Liver Cancer system.
METHODS: A total of 3414 patients were enrolled. The Kaplan-Meier and Cox regression methods were used to determine survival predictors. Akaike information criterion was used to compare the prognostic performance of staging systems.
RESULTS: There were 357 (10%) patients having extrahepatic metastasis at the time of diagnosis. Metastases were associated with old age, alcoholism, hepatitis B, poorer liver function, higher α-foetoprotein level and larger tumour burden (all P < .05). Vascular invasion was associated with metastasis regardless of total tumour volume, and higher α-foetoprotein level and multiple tumours were associated with metastasis in patients with smaller tumour volume (all P < .05). Patients with both vascular invasion and metastasis had significantly worse outcome compared to patients with either vascular invasion or metastasis (P < .05). In the Cox proportional model, the co-existence of vascular invasion and metastasis was an independent predictor of decreased survival (P < .05). Re-allocating 181 Barcelona Clinic Liver Cancer stage C patients with both vascular invasion and metastasis into stage D was associated with lower Akaike information criterion, indicating enhanced prognostic power of the Barcelona Clinic Liver Cancer.
CONCLUSIONS: Metastasis is not uncommon, and is strongly associated with tumoural factors and poor long-term survival in hepatocellular carcinoma. Modification of the Barcelona Clinic Liver Cancer system based on vascular invasion and metastasis may further improve its predictive accuracy in advanced stage patients.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer; hepatocellular carcinoma; metastasis; staging system

Mesh:

Year:  2018        PMID: 29608816     DOI: 10.1111/liv.13748

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Predictors of Macrovascular Invasion and Extrahepatic Metastasis in Treatment Naive Hepatocellular Carcinoma: When Is [18F] FDG PET/CT Relevant?

Authors:  Khangembam Bangkim Chandra; Abhinav Singhal
Journal:  Nucl Med Mol Imaging       Date:  2021-10-04

2.  A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Dig Dis Sci       Date:  2019-10-28       Impact factor: 3.199

3.  ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Cheng-Yuan Hsia; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Heat shock protein A12A activates migration of hepatocellular carcinoma cells in a monocarboxylate transporter 4-dependent manner.

Authors:  Xinxu Min; Xiaofei Cao; Hao Cheng; Ziyang Chen; Xiaojin Zhang; Yunfan Li; Qian Mao; Bin Xue; Lei Fang; Li Liu; Zhengnian Ding
Journal:  Cell Stress Chaperones       Date:  2022-01-20       Impact factor: 3.827

5.  A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-Hsiang Huang; Jia-I Liao; Chien-Wei Su; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.